




Healthcare News Roundup: Biopharmaceuticals
HSMN NewsFeed - 20 May 2022
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
HSMN NewsFeed - 19 May 2022
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
HSMN NewsFeed - 17 May 2022
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 5 May 2022
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
HSMN NewsFeed - 2 May 2022
Supernus Announces FDA Approval of Qelbree(R) for the Treatment of ADHD in Adults
Supernus Announces FDA Approval of Qelbree(R) for the Treatment of ADHD in Adults
HSMN NewsFeed - 2 May 2022
Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar
Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar
HSMN NewsFeed - 29 Apr 2022
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
HSMN NewsFeed - 26 Apr 2022
Halozyme Commences Tender Offer for All Outstanding Shares of Common Stock of Antares Pharma
Halozyme Commences Tender Offer for All Outstanding Shares of Common Stock of Antares Pharma
HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
HSMN NewsFeed - 13 Apr 2022
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
HSMN NewsFeed - 11 Apr 2022
Evofem Announces Karina Fedasz as Company's New Head of Business Development
Evofem Announces Karina Fedasz as Company's New Head of Business Development
HSMN NewsFeed - 4 Apr 2022
Ardelyx Announces US Launch of IBSRELA(R), a New First-in-Class Treatment for IBS-C in Adults
Ardelyx Announces US Launch of IBSRELA(R), a New First-in-Class Treatment for IBS-C in Adults
HSMN NewsFeed - 30 Mar 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
HSMN NewsFeed - 30 Mar 2022
Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease
Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease
HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics